Key Takeaways
- • Apollo Global Management is in advanced talks to acquire Johnson & Johnson's DePuy Synthes orthopedics unit at a valuation near $20 billion, according to Bloomberg reporting independently confirmed by Reuters and The Wall Street Journal as of September 11, 2026.
- • DePuy Synthes generated approximately $9.3 billion in 2025 revenue and manufactures orthopedic devices for hip, knee, and related surgical procedures, positioning it as a scaled, revenue-generating healthcare franchise.
- • J&J publicly committed last year to separate DePuy Synthes into a standalone company within 18–24 months as the parent company refocuses on higher-growth business segments, creating a defined exit window.
- • Multiple private-equity firms have expressed interest in the asset; however, J&J retains the option to execute a public spin-off rather than sell to Apollo or another sponsor, leaving the outcome uncertain.
- • The $20 billion discussion figure represents a negotiated valuation in ongoing talks—not a signed purchase agreement, definitive close date, or final transaction price; deal closure could occur within weeks or talks could terminate without agreement.
Summary
Apollo Global Management is pursuing an acquisition of Johnson & Johnson's DePuy Synthes orthopedics business in negotiations valued near $20 billion, according to multiple credible sources reporting on September 11, 2026. The talks remain active but unresolved, with multiple potential outcomes still possible: a completed transaction, termination of negotiations, competitive bidding by rival sponsors, or J&J's decision to proceed with a public spin-off of the unit instead.
DePuy Synthes is a substantial revenue-generating asset, having posted approximately $9.3 billion in sales during 2025. The company manufactures orthopedic implants and devices used in hip replacements, knee surgeries, and related orthopedic procedures—a recurring-revenue, procedure-linked business model that typically commands premium valuations within healthcare private-equity circles. At the discussed $20 billion valuation, the implied multiple reflects the scale and stability of the franchise, though no EBITDA multiple or detailed transaction economics have been publicly disclosed.
J&J signaled its intent to separate DePuy Synthes approximately one year ago, committing to a spinoff timeline of 18–24 months as the parent corporation reallocates capital toward faster-growing therapeutic areas. Bloomberg's reporting indicates that several private-equity firms beyond Apollo have shown acquisition interest, creating a competitive dynamic that may influence final valuation. However, J&J retains full optionality: the company could execute a traditional public spinoff, sell to Apollo, entertain bids from rival sponsors, or pursue alternative corporate structures.
The $20 billion figure cited in reporting represents the valuation range discussed in current negotiations, not a finalized purchase price or binding commitment. Depending on deal progression, an agreement could materialize within weeks, talks could collapse, or material terms could shift. This transaction, if completed, would represent a major acquisition of a healthcare device franchise by a mega-cap alternative asset manager and reflects ongoing appetite among large sponsors for scaled healthcare infrastructure assets.
DePuy Synthes is a substantial revenue-generating asset, having posted approximately $9.3 billion in sales during 2025. The company manufactures orthopedic implants and devices used in hip replacements, knee surgeries, and related orthopedic procedures—a recurring-revenue, procedure-linked business model that typically commands premium valuations within healthcare private-equity circles. At the discussed $20 billion valuation, the implied multiple reflects the scale and stability of the franchise, though no EBITDA multiple or detailed transaction economics have been publicly disclosed.
J&J signaled its intent to separate DePuy Synthes approximately one year ago, committing to a spinoff timeline of 18–24 months as the parent corporation reallocates capital toward faster-growing therapeutic areas. Bloomberg's reporting indicates that several private-equity firms beyond Apollo have shown acquisition interest, creating a competitive dynamic that may influence final valuation. However, J&J retains full optionality: the company could execute a traditional public spinoff, sell to Apollo, entertain bids from rival sponsors, or pursue alternative corporate structures.
The $20 billion figure cited in reporting represents the valuation range discussed in current negotiations, not a finalized purchase price or binding commitment. Depending on deal progression, an agreement could materialize within weeks, talks could collapse, or material terms could shift. This transaction, if completed, would represent a major acquisition of a healthcare device franchise by a mega-cap alternative asset manager and reflects ongoing appetite among large sponsors for scaled healthcare infrastructure assets.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.